SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YEEHAW CANDIDATES
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Galirayo who wrote (15211)2/9/2006 2:15:58 PM
From: PuddleGlum  Read Replies (2) of 23958
 
SGMO moving well on some news:

"The data demonstrate that Sangamo's ZFP nuclease (ZFN(TM)) technology can be used to make cells resistant to HIV infection by permanently modifying the DNA sequence encoding CCR5, an essential co-receptor for the entry of HIV into immune cells. In the second half of 2006, Sangamo intends to initiate a Phase 1 clinical trial to test this HIV ZFP Therapeutic, working in close collaboration with Dr. Carl June of the University of Pennsylvania School of Medicine."

There are plans to initiate Phase I trials, so we might be a little ways from having a product on the market. A little ways, like 5-10 years?

But the chart is very nice:
stockcharts.com[PA][D][F1!3!1.67!!2!20]&pref=G
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News